CL2015003738A1 - Formulación líquida estable de amg-416 (velcalcetida) - Google Patents

Formulación líquida estable de amg-416 (velcalcetida)

Info

Publication number
CL2015003738A1
CL2015003738A1 CL2015003738A CL2015003738A CL2015003738A1 CL 2015003738 A1 CL2015003738 A1 CL 2015003738A1 CL 2015003738 A CL2015003738 A CL 2015003738A CL 2015003738 A CL2015003738 A CL 2015003738A CL 2015003738 A1 CL2015003738 A1 CL 2015003738A1
Authority
CL
Chile
Prior art keywords
velcalcetide
amg
liquid formulation
stable liquid
stable
Prior art date
Application number
CL2015003738A
Other languages
English (en)
Inventor
Derek Maclean
Qun Yin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51213030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015003738(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2015003738A1 publication Critical patent/CL2015003738A1/es

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04D—NON-POSITIVE-DISPLACEMENT PUMPS
    • F04D25/00—Pumping installations or systems
    • F04D25/02—Units comprising pumps and their driving means
    • F04D25/06—Units comprising pumps and their driving means the pump being electrically driven
    • F04D25/0606—Units comprising pumps and their driving means the pump being electrically driven the electric motor being specially adapted for integration in the pump
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
    • F01D15/00—Adaptations of machines or engines for special use; Combinations of engines with devices driven thereby
    • F01D15/10—Adaptations for driving, or combinations with, electric generators

Abstract

FORMULACION FARMCEUTICA QUE COMPRENDE AMG416 EN SOLUCION ACUOSA CON UN PH DE 2,0 A 5,0.
CL2015003738A 2013-06-28 2015-12-28 Formulación líquida estable de amg-416 (velcalcetida) CL2015003738A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361840618P 2013-06-28 2013-06-28

Publications (1)

Publication Number Publication Date
CL2015003738A1 true CL2015003738A1 (es) 2016-12-09

Family

ID=51213030

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003738A CL2015003738A1 (es) 2013-06-28 2015-12-28 Formulación líquida estable de amg-416 (velcalcetida)

Country Status (38)

Country Link
US (4) US9820938B2 (es)
EP (3) EP3013318B1 (es)
JP (1) JP6027708B2 (es)
KR (1) KR102231957B1 (es)
CN (2) CN114376970A (es)
AP (1) AP2015008936A0 (es)
AR (1) AR096773A1 (es)
AU (1) AU2014302122B2 (es)
CA (1) CA2916222C (es)
CL (1) CL2015003738A1 (es)
CR (2) CR20160061A (es)
CY (1) CY1120811T1 (es)
DK (1) DK3013318T3 (es)
EA (1) EA030220B1 (es)
ES (1) ES2633989T3 (es)
HK (1) HK1222557A1 (es)
HR (1) HRP20171092T1 (es)
HU (1) HUE034209T2 (es)
IL (1) IL243210B (es)
JO (1) JO3817B1 (es)
LT (1) LT3013318T (es)
MA (1) MA38724B1 (es)
ME (1) ME02818B (es)
MX (1) MX2015017952A (es)
MY (1) MY180276A (es)
PE (2) PE20160549A1 (es)
PH (1) PH12015502816A1 (es)
PL (1) PL3013318T3 (es)
PT (1) PT3013318T (es)
RS (1) RS56238B1 (es)
SG (1) SG11201510647TA (es)
SI (1) SI3013318T1 (es)
TN (1) TN2015000569A1 (es)
TW (1) TWI635874B (es)
UA (1) UA115373C2 (es)
UY (1) UY35636A (es)
WO (1) WO2014210489A1 (es)
ZA (1) ZA201600238B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3013318B1 (en) 2013-06-28 2017-04-19 Amgen Inc. Stable liquid formulation of amg 416 (velcalcetide)
HUE048489T2 (hu) 2014-04-03 2020-07-28 Amgen Inc Eljárás AMG 416 elõállítására
CA2980960A1 (en) 2015-03-26 2016-09-29 Amgen Inc. Solution phase method for preparing etelcalcetide
CN106137979A (zh) * 2015-03-31 2016-11-23 深圳翰宇药业股份有限公司 一种冻干粉针剂及其制备方法
CN106928320B (zh) 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN110054662B (zh) * 2018-01-18 2021-03-02 成都圣诺生物制药有限公司 一种固相合成Etelcalcetide的方法
MX2022014369A (es) 2020-05-15 2023-02-23 Amgen Inc Métodos de tratamiento de la hipertrofia del ventrículo izquierdo.
CN111925415A (zh) * 2020-08-10 2020-11-13 海南中和药业股份有限公司 一种维拉卡肽杂质的制备方法
WO2022034545A1 (en) * 2020-08-14 2022-02-17 Aurobindo Pharma Limited Etelcalcetide formulations for parenteral use
EP4333805A1 (en) 2021-05-06 2024-03-13 Amgen Inc. Etelcalcetide formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5158098A (en) 1996-10-25 1998-05-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions for inhibiting inflammation and angiogenesis compri sing a mammalian CD97 alpha subunit
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
CA2527743A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN102940879B (zh) * 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
JP5645408B2 (ja) * 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
JP2010516707A (ja) * 2007-01-19 2010-05-20 カイ ファーマシューティカルズ インコーポレーティッド ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
ES2412707T5 (es) 2009-06-19 2023-06-12 Procter & Gamble Composición detergente líquida para lavado de vajillas a mano
ES2607954T3 (es) 2009-07-29 2017-04-04 Kai Pharmaceuticals, Inc. Agentes terapéuticos para reducir los niveles de hormona paratiroidea
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
WO2012075375A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
LT2717896T (lt) * 2011-06-08 2017-02-27 Kai Pharmaceuticals, Inc. Terapiniai agentai, skirti fosforo koncentracijos serume reguliavimui
MX355063B (es) * 2011-11-10 2018-04-04 Kai Pharmaceuticals Inc Calcimiméticos y métodos para su uso.
EP3013318B1 (en) 2013-06-28 2017-04-19 Amgen Inc. Stable liquid formulation of amg 416 (velcalcetide)
HUE048489T2 (hu) * 2014-04-03 2020-07-28 Amgen Inc Eljárás AMG 416 elõállítására

Also Published As

Publication number Publication date
HUE034209T2 (en) 2018-02-28
US11162500B2 (en) 2021-11-02
US20220042515A1 (en) 2022-02-10
US11959486B2 (en) 2024-04-16
EA201690099A1 (ru) 2016-06-30
PH12015502816B1 (en) 2016-03-21
IL243210B (en) 2020-02-27
ZA201600238B (en) 2017-05-31
PT3013318T (pt) 2017-07-24
AU2014302122A1 (en) 2016-01-21
SI3013318T1 (sl) 2017-11-30
CA2916222A1 (en) 2014-12-31
CN114376970A (zh) 2022-04-22
US10344765B2 (en) 2019-07-09
TW201542239A (zh) 2015-11-16
EP3013318A1 (en) 2016-05-04
AR096773A1 (es) 2016-02-03
TWI635874B (zh) 2018-09-21
KR20160043954A (ko) 2016-04-22
AP2015008936A0 (en) 2015-12-31
HK1222557A1 (zh) 2017-07-07
DK3013318T3 (en) 2017-08-07
EA030220B1 (ru) 2018-07-31
US20190285074A1 (en) 2019-09-19
SG11201510647TA (en) 2016-01-28
US20160220486A1 (en) 2016-08-04
ME02818B (me) 2018-01-20
MY180276A (en) 2020-11-26
EP3878433A1 (en) 2021-09-15
JP6027708B2 (ja) 2016-11-16
RS56238B1 (sr) 2017-11-30
BR112015032615A2 (pt) 2017-07-25
CN105764487A (zh) 2016-07-13
MA38724A1 (fr) 2017-03-31
CA2916222C (en) 2021-05-18
ES2633989T3 (es) 2017-09-26
EP3013318B1 (en) 2017-04-19
LT3013318T (lt) 2017-09-11
JP2016523916A (ja) 2016-08-12
CR20160002A (es) 2018-02-13
CY1120811T1 (el) 2019-12-11
JO3817B1 (ar) 2021-01-31
KR102231957B1 (ko) 2021-03-25
MA38724B1 (fr) 2017-11-30
EP3246017B1 (en) 2021-03-24
NZ715403A (en) 2020-10-30
PH12015502816A1 (en) 2016-03-21
PL3013318T3 (pl) 2018-03-30
AU2014302122B2 (en) 2018-12-06
EP3246017A1 (en) 2017-11-22
WO2014210489A1 (en) 2014-12-31
HRP20171092T1 (hr) 2017-10-06
CR20160061A (es) 2016-09-28
UA115373C2 (uk) 2017-10-25
PE20210413A1 (es) 2021-03-04
US20180080452A1 (en) 2018-03-22
MX2015017952A (es) 2016-10-28
UY35636A (es) 2015-01-30
IL243210A0 (en) 2016-02-29
PE20160549A1 (es) 2016-06-15
US9820938B2 (en) 2017-11-21
TN2015000569A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
CL2015003738A1 (es) Formulación líquida estable de amg-416 (velcalcetida)
BR112015020795A2 (pt) derivados de pirazol novos
EA201792613A1 (ru) Модуляторы cot и способы их применения
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
GT201400144A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112015009600A2 (pt) piridina-2-amidas úteis como agonistas cb2
EA201590807A1 (ru) Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций
BR112015013124A2 (pt) novos derivados de piridina
IN2014CN00797A (es)
PH12016500720A1 (en) Stable formulation of insulin glulisine
CR20150440A (es) Nuevos derivados de piridina
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
CR20150511A (es) Nuevos derivados de purina
TWD189982S (zh) 注射裝置的容器
CR20160448A (es) Nuevos derivados de piridina
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease
BR112015030824A2 (pt) novos derivados de tetrazolona
BR112015030129A2 (pt) ésteres sulfatados de ácido oligohidróxi carboxílico e seu uso
BR112015030135A2 (pt) ésteres de ácidos oligo-hidróxi carboxílicos e seu uso
BR112014019220A8 (pt) Novos derivados de pirrolidina
CL2016000397A1 (es) Tratamiento contra el cáncer